The focuses of the bill include stifling the influx of opioid importation, emphasizing recovery from addiction, and providing alternative drugs that carry lessened risks.
Despite the bill’s staunch approach towards harm reduction, The Kratom Trade Association confirmed that OCRA doesn’t contain a single mention of kratom, nor does it create an opportunity for expedited scheduling.
This news comes as a victory to many American kratom advocates, who have been concerned regarding the final wording of the bill and the regulatory ramifications that could follow if kratom was included. These fears have been stirred by the recent campaigns of both the United States FDA and DEA, with both organizations declaring an interest in regulating and/or illegalizing the plant. Both federal organizations have repeatedly drawn comparisons between kratom and opioids (FDA, DEA)